Strut Health review: oral semaglutide lozenges $99-$149/mo, injectable $149-$289/mo, FDA warning letter Feb 2026, D+ BBB rating, cancellation friction. Compared to PlexusDx Microdose GLP-1 ($129/mo), Semaglutide Injection ($179-$229/mo), and Tirzepatide Injection ($229-$309/mo) with the optional Precision Peptide Genetic Test for dose personalization.

Compounding pharmacy shut down or lost 503A status for GLP-1s? A 2026 patient continuity guide: first 24-hour checklist, the four scenarios, what a warning letter actually means, three pharmacy-verification lookups, and how PlexusDx Semaglutide Injection ($179-$229/mo), Tirzepatide Injection ($229-$309/mo), Microdose GLP-1 Protocol ($129/mo), GLP-Squared ($179-$325/mo), and the Precision Peptide Genetic Test ($99 add-on) handle transfer patients.

An honest, verified review of Skinny Rx tirzepatide tablets — the $299/month buccal-dissolve compounded product, the February 2026 FDA warning letter, and the actual evidence picture for any oral tirzepatide formulation — with a feature-by-feature comparison to PlexusDx Tirzepatide Oral Protocol ($229–$509/mo, 5mg to 25mg daily across seven dose levels) as the cash-pay alternative.

MEDVi, Remedy Meds, and PlexusDx all dispense compounded semaglutide and tirzepatide — but the annualized cost, billing cadence, and clinical-oversight model differ in ways the landing pages don't show. This guide walks the real numbers, the September 2025 FDA warning-letter context, and where PlexusDx Weight Management Protocols ($129–$325/mo) plus the Precision Peptide Genetic Test fit relative to both.

MEDVi vs Gala GLP-1 vs PlexusDx compared on verified 2026 pricing, compounded vs FDA-approved status, cancellation rules, and where a genetic baseline changes the dose decision before week one.